BRIANNE AYERS: Open Payments
NPI 1407225212 · BOISE, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,158 in 52 payments from 16 companies in 2025. Trend: 2023 $528 · 2024 $911 · 2025 $1,158
Food & beverage: $1,099Education: $59
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 14 | $170 |
| AstraZeneca Pharmaceuticals LP | 3 | $155 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $155 |
| Amgen Inc. | 4 | $87 |
| CSL Behring | 4 | $83 |
| GENZYME CORPORATION | 2 | $81 |
| Ionis Pharmaceuticals, Inc. | 3 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $70 |
| Novartis Pharmaceuticals Corporation | 2 | $53 |
| Incyte Corporation | 3 | $52 |
Products named: NEFFY, AIRSUPRA, NUCALA, AYVAKIT, TEZSPIRE, Hizentra, DUPIXENT, TRELEGY ELLIPTA.
Industry payments across ID — which companies pay providers there.
